Herttua Kimmo, Martikainen Pekka, Batty G David, Kivimäki Mika
Centre of Maritime Health and Society, Department of Public Health, University of Southern Denmark, Esbjerg, Denmark; Population Research Unit, Department of Social Research, University of Helsinki, Helsinki, Finland.
Population Research Unit, Department of Social Research, University of Helsinki, Helsinki, Finland; Centre for Health Equity Studies (CHESS), Stockholm University and Karolinska Institutet, Stockholm, Sweden; The Max Planck Institute for Demographic Research, Rostock, Germany.
J Am Coll Cardiol. 2016 Apr 5;67(13):1507-1515. doi: 10.1016/j.jacc.2016.01.044.
Poor adherence to medication regimens is common, potentially contributing to the occurrence of related disease.
The authors sought to assess the risk of fatal stroke associated with nonadherence to statin and/or antihypertensive therapy.
We conducted a population-based study using electronic medical and prescription records from Finnish national registers in 1995 to 2007. Of the 58,266 hypercholesterolemia patients age 30+ years without pre-existing stroke or cardiovascular disease, 532 patients died of stroke (cases), and 57,734 remained free of incident stroke (controls) during the mean follow-up of 5.5 years. We captured year-by-year adherence to statin and antihypertensive therapy in both study groups and estimated the excess risk of stroke death associated with nonadherence.
In all hypercholesterolemia patients, the adjusted odds ratio for stroke death for nonadherent compared with adherent statin users was 1.35 (95% confidence interval [CI] 1.04 to 1.74) 4 years before and 2.04 (95% CI: 1.72 to 2.43) at the year of stroke death or the end of the follow-up. In hypercholesterolemia patients with hypertension, relative to those who adhered to statins and antihypertensive therapy, the odds ratio at the year of stroke death was 7.43 (95% CI: 5.22 to 10.59) for those nonadherent both to statin and antihypertensive therapy, 1.82 (95% CI: 1.43 to 2.33) for those non-adherent to statin but adherent to antihypertensive therapy, and 1.30 (95% CI: 0.53 to 3.20) for those adherent to statin, but nonadherent to antihypertensive, therapy.
Individuals with hypercholesterolemia and hypertension who fail to take their prescribed statin and antihypertensive medication experience a substantially increased risk of fatal stroke. The risk is lower if the patient is adherent to either one of these therapies.
药物治疗方案依从性差很常见,可能导致相关疾病的发生。
作者试图评估与不坚持服用他汀类药物和/或抗高血压药物治疗相关的致命性中风风险。
我们利用1995年至2007年芬兰国家登记处的电子医疗和处方记录进行了一项基于人群的研究。在58266名年龄30岁及以上且无既往中风或心血管疾病的高胆固醇血症患者中,532例患者死于中风(病例组),57734例在平均5.5年的随访期间未发生中风(对照组)。我们记录了两个研究组逐年的他汀类药物和抗高血压药物治疗依从性,并估计了与不依从相关的中风死亡额外风险。
在所有高胆固醇血症患者中,与坚持服用他汀类药物的患者相比,不坚持服用他汀类药物的患者中风死亡的校正比值比在中风死亡前4年为1.35(95%置信区间[CI]1.04至1.74),在中风死亡当年或随访结束时为2.04(95%CI:1.72至2.43)。在患有高血压的高胆固醇血症患者中,相对于坚持服用他汀类药物和抗高血压药物治疗的患者,在中风死亡当年,既不坚持服用他汀类药物也不坚持服用抗高血压药物的患者的比值比为7.43(95%CI:5.22至10.59),不坚持服用他汀类药物但坚持服用抗高血压药物的患者为1.82(95%CI:1.43至2.33),坚持服用他汀类药物但不坚持服用抗高血压药物治疗的患者为1.30(95%CI:0.53至